There is a wide range of clinical trials evaluating drug-eluting, bare, and resorbable coronary stents for their safety, efficacy and performance. Below are many of the key trials in process or completed.
ARRIVE II Registry
SIRIUS, E-SIRIUS, C-SIRIUS
Source: Report #C245, "Worldwide Coronary Stents, 2009-2018."
These trials are described in the business market analysis from MedMarket Diligence, LLC, Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017," publishing March/April 2009.
This report details the worldwide market for the use of coronary stents in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types. The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.